Non‑Selective Non‑Steroidal Anti‑Inflammatory Drugs (NSAIDs): Salicylates and Propionic Acid Derivatives

Introduction / Overview

Non‑selective NSAIDs comprise a broad class of agents that inhibit cyclo‑oxygenase (COX) enzymes and thereby reduce the synthesis of prostaglandins, thromboxanes, and leukotrienes. Among them, salicylates and propionic acid derivatives represent the most widely used and clinically relevant subgroups. These drugs are indispensable for the management of acute and chronic pain, fever, and inflammatory disorders, and they play a pivotal role in antiplatelet therapy for cardiovascular disease prevention. The prevalence of their use, coupled with their complex pharmacology and potential for adverse reactions, underscores the necessity for a detailed understanding of these agents by medical and pharmacy professionals.

Learning Objectives

• Describe the chemical and pharmacological classification of salicylates and propionic acid NSAIDs.
• Explain the mechanism of action, including COX inhibition and downstream effects on prostanoid synthesis.
• Summarize key pharmacokinetic properties that influence dosing and therapeutic monitoring.
• Identify principal therapeutic indications and common off‑label uses.
• Recognize major adverse effects, drug interactions, and patient‑specific considerations that impact clinical decision‑making.

Classification

Drug Classes and Categories

Non‑selective NSAIDs are traditionally divided into three principal chemical families: salicylates, propionic acid derivatives, and other miscellaneous compounds (e.g., indomethacin, diclofenac). For the purpose of this chapter, focus is placed on salicylates and propionic acid derivatives due to their clinical prominence.

Salicylates

• Aspirin (acetylsalicylic acid) – the prototype salicylate, commonly used at low doses for antiplatelet effects and at higher doses for analgesia and anti‑inflammation.
• Sodium salicylate – primarily employed for its antipyretic and anti‑inflammatory properties in pediatric and adult populations.
• Other salicylate derivatives (e.g., phenyl salicylate) – less frequently used and largely relegated to experimental or niche therapeutic contexts.

Propionic Acid Derivatives

• Ibuprofen – a non‑steroidal anti‑inflammatory agent with rapid onset of action.
• Naproxen – distinguished by a longer duration of action owing to a slower dissociation from COX enzymes.
• Ketorolac – a potent short‑acting NSAID reserved for peri‑operative and acute pain settings.
• Diclofenac – notable for its high potency and distinct pharmacokinetic profile, often delivered via topical or transdermal routes.
• Other propionic acid derivatives (e.g., piroxicam, meloxicam) – though meloxicam is more selective for COX‑2, it is still frequently categorized within this group for historical reasons.

Mechanism of Action

Pharmacodynamics

Non‑selective NSAIDs exert their therapeutic effects principally through inhibition of cyclo‑oxygenase enzymes, COX‑1 and COX‑2, which catalyze the conversion of arachidonic acid to prostaglandin H₂ (PGH₂). PGH₂ serves as a substrate for downstream synthases that generate prostaglandins (e.g., PGE₂, PGI₂) and thromboxane A₂ (TXA₂). By blocking COX activity, these drugs reduce prostaglandin production, thereby attenuating inflammation, pain, and fever. In addition, low‑dose aspirin irreversibly acetylates a serine residue (Ser530) in the COX‑1 active site, leading to permanent inhibition of TXA₂ synthesis in platelets and conferring antithrombotic benefit.

Receptor Interactions

Prostaglandins act via specific G‑protein coupled receptors: EP1‑EP4 for PGE₂, IP for prostacyclin, TP for thromboxane A₂, and others. Inhibition of prostaglandin synthesis diminishes receptor activation, thereby reducing vasodilation, vascular permeability, and nociceptor sensitization. The attenuation of PGE₂ signaling is particularly relevant for analgesia, as PGE₂ sensitizes peripheral nociceptors and contributes to central sensitization.

Molecular/Cellular Mechanisms

At the cellular level, NSAIDs disrupt the arachidonic acid cascade by competitively binding to the COX active site. The non‑selective inhibition of COX‑1 compromises gastric mucosal protection, renal prostaglandin production, and platelet aggregation. The dual COX inhibition also leads to a shift in the balance of prostaglandins toward leukotriene synthesis via the 5‑lipoxygenase pathway, potentially contributing to hypersensitivity reactions in susceptible individuals. Aspirin’s irreversible acetylation of COX‑1 results in a prolonged antiplatelet effect, whereas propionic acid derivatives typically exhibit reversible, competitive inhibition with variable duration of action.

Pharmacokinetics

Absorption

All salicylates and propionic acid derivatives are orally administered and absorbed primarily in the small intestine. Peak plasma concentrations are generally attained within 30–90 minutes for propionic acid NSAIDs, whereas aspirin reaches maximum levels within 15–30 minutes. Bioavailability varies: aspirin is nearly 100 % bioavailable orally, whereas ibuprofen and naproxen exhibit bioavailability ranging from 50–80 % due to first‑pass metabolism.

Distribution

These agents are extensively distributed throughout body tissues, achieving high concentrations in inflamed sites. Protein binding is significant; aspirin binds to albumin and α‑1‑acid glycoprotein, while ibuprofen and naproxen demonstrate >90 % binding. The high degree of binding influences both efficacy and the potential for drug‑drug interactions, as displacement can alter free drug concentrations.

Metabolism

Aspirin is rapidly hydrolyzed to salicylic acid, which is further conjugated via glucuronidation and sulfation. Propionic acid NSAIDs undergo hepatic metabolism predominantly through cytochrome P450 enzymes (CYP2C9 for ibuprofen, CYP2C8 for naproxen). The metabolites are generally inactive or less active; however, the formation of reactive intermediates may contribute to idiosyncratic hepatotoxicity in some patients.

Excretion

Salicylate metabolites are excreted via the kidneys, primarily through glomerular filtration and tubular secretion. Renal clearance is the main route of elimination for both aspirin and propionic acid derivatives, with elimination half‑lives ranging from 1–3 hours for ibuprofen to 12–17 hours for naproxen, depending on dose and renal function. Impaired renal function prolongs half‑life and increases the risk of accumulation.

Dosing Considerations

Therapeutic dosing is guided by the desired effect: low‑dose aspirin (75–100 mg daily) is reserved for antiplatelet therapy, whereas higher doses (up to 400 mg every 6–8 hours) are used for analgesia. Propionic acid NSAIDs are typically dosed every 6–8 hours, with maximum daily limits (e.g., 1200 mg for ibuprofen). Dose adjustments are required for the elderly, patients with renal insufficiency, or those with hepatic impairment, due to altered clearance and increased sensitivity to adverse effects.

Therapeutic Uses / Clinical Applications

Approved Indications

• Aspirin – antiplatelet therapy for secondary prevention of myocardial infarction and ischemic stroke; analgesia, anti‑inflammatory, and antipyretic use at higher doses.
• Ibuprofen – acute pain (musculoskeletal, dental, postoperative), dysmenorrhea, low‑grade fever.
• Naproxen – osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout flares, dysmenorrhea, acute pain.
• Ketorolac – short‑term management of moderate to severe acute pain, especially peri‑operative settings.
• Diclofenac – osteoarthritis, rheumatoid arthritis, postoperative pain, topical formulations for localized conditions.

Off‑Label Uses

NSAIDs are frequently employed in several off‑label contexts, including migraine prophylaxis (especially with naproxen or ibuprofen), low‑dose aspirin for primary cardiovascular prevention (though guidelines vary), and prophylaxis of postoperative nausea in selected patients. Some propionic acid NSAIDs are utilized in veterinary medicine for analgesia and anti‑inflammation in companion animals.

Adverse Effects

Common Side Effects

• Gastro‑intestinal (GI) – dyspepsia, nausea, abdominal pain, gastritis, ulceration, and bleeding. These are dose‑related and more pronounced with high‑dose or long‑term use.
• Renal effects – acute kidney injury due to reduced prostaglandin‑mediated renal vasodilation, particularly in volume‑depleted states or in patients with chronic kidney disease.
• Hepatotoxicity – elevated transaminases and, rarely, cholestatic hepatitis, more common with high doses or chronic use.
• Hypersensitivity reactions – urticaria, angioedema, bronchospasm, and, in rare cases, anaphylaxis.
• Central nervous system effects – headache, dizziness, tinnitus, especially at high plasma concentrations.

Serious / Rare Adverse Reactions

• Bleeding diathesis – particularly when combined with anticoagulants or antiplatelet agents.
• Severe GI ulceration with perforation or obstruction.
• Acute interstitial nephritis and renal failure.
• Reye syndrome in children and adolescents with viral infections.
• Allergic bronchopulmonary disease exacerbation in patients with asthma or aspirin‑exacerbated respiratory disease (AERD).

Black Box Warnings

Low‑dose aspirin carries a black box warning for increased risk of gastric bleeding and hemorrhagic stroke. Long‑term use of high‑dose NSAIDs is also associated with a heightened risk of GI bleeding, requiring concurrent gastroprotective strategies in high‑risk patients.

Drug Interactions

Major Drug‑Drug Interactions

• Anticoagulants (warfarin, DOACs) – NSAIDs potentiate anticoagulant effects, increasing bleeding risk.
• Angiotensin‑converting enzyme (ACE) inhibitors and angiotensin receptor blockers – NSAIDs can attenuate the antihypertensive response and precipitate renal dysfunction.
• Diuretics (thiazides, loop diuretics) – combined use raises the risk of renal impairment and hyperkalemia.
• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs) – enhanced bleeding tendency.
• Potassium‑sparing diuretics – NSAID‑induced sodium retention may lead to hyperkalemia.
• Other NSAIDs or COX‑2 inhibitors – additive GI and renal toxicity.

Contraindications

Absolute contraindications include active peptic ulcer disease, history of GI bleeding, severe renal or hepatic impairment, hypersensitivity to NSAIDs, and concurrent anticoagulant therapy without gastroprotection. Relative contraindications include uncontrolled hypertension, heart failure, and pregnancy (especially in the third trimester).

Special Considerations

Pregnancy / Lactation

NSAIDs are generally contraindicated in the third trimester due to the risk of premature ductus arteriosus closure and oligohydramnios. First‑trimester exposure may increase miscarriage risk. During lactation, low‑dose aspirin is considered acceptable, whereas high‑dose propionic acid NSAIDs should be avoided because of potential adverse effects on the nursing infant’s renal function and platelet activity.

Pediatric / Geriatric Considerations

In pediatrics, dosing is weight‑based, and caution is advised to avoid Reye syndrome. Geriatric patients exhibit decreased renal clearance and increased sensitivity to GI side effects, necessitating lower doses and the use of gastroprotective agents (e.g., proton pump inhibitors). Regular monitoring of renal function and complete blood counts is advisable in older adults on chronic NSAID therapy.

Renal / Hepatic Impairment

Patients with chronic kidney disease (CKD) should receive reduced dosages to mitigate the risk of further renal injury. Hepatic impairment may prolong drug clearance and increase hepatotoxicity risk; therefore, careful monitoring of liver function tests is essential. In severe hepatic dysfunction, NSAIDs are generally avoided.

Summary / Key Points

Key Points

• Non‑selective NSAIDs exert anti‑inflammatory, analgesic, and antipyretic effects through COX‑1/COX‑2 inhibition.
• Aspirin’s irreversible acetylation of COX‑1 underlies its antiplatelet utility at low doses.
• Propionic acid derivatives are characterized by rapid absorption and variable pharmacokinetics that necessitate dose adjustments in renal or hepatic compromise.
• GI, renal, and hepatotoxic adverse effects are dose‑dependent and can be mitigated with concurrent gastroprotective therapy and judicious dosing.
• Drug interactions, particularly with anticoagulants and antihypertensives, can potentiate bleeding and renal dysfunction, warranting careful medication reconciliation.
• Special populations (pregnancy, lactation, pediatrics, geriatrics) require individualized dosing and monitoring strategies.
• Clinicians should remain vigilant for signs of hypersensitivity, especially in patients with aspirin‑exacerbated respiratory disease.

Clinical pearls include the use of the lowest effective dose for the shortest possible duration, the addition of gastroprotective agents in high‑risk patients, and the importance of patient education regarding potential adverse effects and drug interactions.

References

1. Fishman SM, Ballantyne JC, Rathmell JP. Bonica's Management of Pain. 5th ed. Philadelphia: Wolters Kluwer; 2018.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.